NCT05328726View on ClinicalTrials.gov

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

February 9, 2023

Study Completion Date

March 9, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GZR-18

As previously described in Arms

OTHER

Placebo

Placebo will be dosed in an identical manner to active study drug.

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY